Spirogen has a broad pipeline of products in pre-clinical development and one compound, SG2000, in Phase I with Phase II entry planned for Q3 2008 clinical evaluation.
| Agent | Indication | Stage of Development | |||
| Discovery | Pre-clinical | Phase One | Phase Two | ||
| SG2000 | ONCOLOGY |  |
|||
| SG2285 | ONCOLOGY | |
|||
| AS-1-145 | ANTI-INFECTIVE | |
|||
| SG2274 | ONCOLOGY | |
|||
